Protalix News
Most Popular Protalix Story
Jumping into rare diseases, Pfizer inks $115M Protalix deal
Pfizer is plunking down $60 million upfront and promising up to $55 million in milestones to license the worldwide rights to Protalix's drug for Gaucher disease--a move the puts the global pharma Read more...
Latest Headlines
- December 6, 2011
- September 8, 2011
- February 25, 2011
- August 12, 2010
- February 12, 2010
- February 11, 2010
- February 2, 2010
- December 10, 2009
- December 1, 2009
- November 2, 2009
- October 15, 2009
- August 25, 2009
- August 17, 2009
- July 6, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
